Women preparing for major gynecologic surgeries often get their vaginas cleaned with antiseptic solutions. Doctors have long debated whether to use chlorhexidine gluconate or povidone iodine. A new analysis of nearly 10,000 patients looked at this choice carefully. The goal was to see if one method prevents infections better than the other. The study combined data from many different trials to get a clear picture. Results showed no meaningful difference in surgical site infections between the two cleaning methods. This means the choice does not change the risk of getting an infection at the surgery site. However, the data did show a higher risk of urinary tract infections when using chlorhexidine. This risk was seen in a specific group of patients within the larger study. The cleaning solution also caused vaginal irritation in some cases. These side effects matter for patient comfort and recovery. The review supports current medical guidelines that allow either product for preventing surgical infections. But doctors should be aware of the urinary infection risk linked to chlorhexidine. More research is needed to fully understand this specific risk. Until then, the choice between these two common cleaners remains a valid clinical decision.
Meta-Analysis Shows No SSI Difference Between Chlorhexidine and Povidone Iodine for Vaginal AntisepsisVaginal cleaning with chlorhexidine does not prevent infections better than iodine in major gynecologic surgeries
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This systematic review and meta-analysis examined vaginal antisepsis practices in patients undergoing major gynecologic operations. The study included 9538 patients and compared chlorhexidine gluconate with povidone iodine. The primary outcome assessed was the rate of surgical site infections. Secondary outcomes included urinary tract infections and vaginal irritation.
The analysis found no statistically significant difference in surgical site infections between the two agents. The relative risk was 1.20 with a 95% CI of 0.92-1.57 based on data from 9538 patients. Consequently, the form of vaginal antisepsis can be used for SSI prevention according to current guidelines supported by these findings.
However, urinary tract infections showed a significantly higher risk for chlorhexidine gluconate. The relative risk was 1.48 with a 95% CI of 1.03-2.14 in a subset of 6061 patients. Vaginal irritation was noted as an adverse event. The authors note that further randomized studies are needed to support findings regarding UTIs.
Practice relevance is tempered by the need for additional research on infection risks. The certainty of the evidence regarding urinary tract infections remains uncertain. Clinicians should weigh the lack of SSI benefit against the potential increase in UTIs when selecting an agent.